Generic Medicine Info
Indications and Dosage
Ocular infections
Adult: As 1% ophthalmic ointment: Apply sparingly into the affected eye(s) 3-4 times daily. Dosage recommendations may vary among individual products or between countries (refer to detailed product guidelines).
Adverse Reactions
General disorders and administration site conditions: Local irritation at the site of application.
Immune system disorders: Hypersensitivity reaction.
Skin and subcutaneous tissue disorders: Photosensitivity, skin rash.
Mechanism of Action: Chlortetracycline is a tetracycline derivative that prevents protein synthesis by binding with the 30S and possibly 50S ribosomal subunit(s) of susceptible bacteria. It has a broad-spectrum antimicrobial activity against Gram-positive and Gram-negative organisms.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 54675777, Chlortetracycline. Accessed May 30, 2023.

Store below 30°C. Protect from light.
MIMS Class
Eye Anti-Infectives & Antiseptics
ATC Classification
S01AA02 - chlortetracycline ; Belongs to the class of antibiotics. Used in the treatment of eye infections.
Anon. Chlortetracycline. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 04/05/2023.

Buckingham R (ed). Chlortetracycline. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 04/05/2023.

Chlortralim (Atlantic Laboratories Corp., Ltd). MIMS Thailand. Accessed 19/05/2023.

Chlortralim Ophthalmic Ointment (Atlantic Laboratories [M] Sdn Bhd). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. Accessed 04/05/2023.

Disclaimer: This information is independently developed by MIMS based on Chlortetracycline from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
  • Chlortralim
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in